BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments, has announced a strategic equity investment in Axis Integrated Mental Health, a Colorado-based mental health clinic management services organization. The investment consists of an initial $2.3 million with a potential additional $1 million milestone-based investment for a minority stake in Axis.
This investment follows BrainsWay's previous stake in Stella and aligns with the company's strategy to accelerate access to innovative mental health treatments, including their Deep TMS Therapy. The investment will be structured as a preferred, annually compounding security with a redemption mechanism, enabling Axis to expand its services and grow from a regional platform to a larger footprint.
BrainsWay (NASDAQ & TASE: BWAY), leader nelle terapie neurostimolatorie non invasive, ha annunciato un investimento azionario strategico in Axis Integrated Mental Health, un鈥檕rganizzazione con sede in Colorado che fornisce servizi di gestione per cliniche di salute mentale. L鈥檌nvestimento prevede un impegno iniziale di 2,3 milioni di dollari con la possibilit脿 di un ulteriore investimento milestone di 1 milione di dollari per acquisire una partecipazione di minoranza in Axis.
Questa operazione segue la partecipazione precedente di BrainsWay in Stella e si inserisce nella strategia dell鈥檃zienda di velocizzare l鈥檃ccesso a trattamenti innovativi per la salute mentale, incluso il loro Deep TMS Therapy. L鈥檌nvestimento sar脿 strutturato come titolo privilegiato con capitalizzazione annuale e meccanismo di rimborso, permettendo ad Axis di ampliare i servizi e passare da piattaforma regionale a presenza pi霉 estesa.
BrainsWay (NASDAQ & TASE: BWAY), l铆der en tratamientos de neuroestimulaci贸n no invasiva, ha anunciado una inversi贸n accionaria estrat茅gica en Axis Integrated Mental Health, una organizaci贸n de servicios de gesti贸n de cl铆nicas de salud mental con sede en Colorado. La inversi贸n incluye un desembolso inicial de 2,3 millones de d贸lares y la posibilidad de un inversi贸n adicional basada en hitos de 1 mill贸n de d贸lares para adquirir una participaci贸n minoritaria en Axis.
Esta inversi贸n sigue la participaci贸n previa de BrainsWay en Stella y se alinea con la estrategia de la compa帽铆a de acelerar el acceso a tratamientos mentales innovadores, incluido su Deep TMS Therapy. La operaci贸n se estructurar谩 como un t铆tulo preferente con capitalizaci贸n anual y un mecanismo de redenci贸n, lo que permitir谩 a Axis ampliar sus servicios y crecer de una plataforma regional a una presencia mayor.
BrainsWay (NASDAQ & TASE: BWAY), 牍勳龚鞀奠爜 鞁犼步鞛愱饭 旃橂 攵勳暭鞚� 靹犽弰 旮办梾鞚� 旖滊霛茧弰鞐� 旮半皹鞚� 霊� 鞝曥嫚瓯搓皶 韥措Μ雼� 甏�毽� 靹滊箘鞀� 臁办鞚� Axis Integrated Mental Health鞐� 鞝勲灥鞝� 歆�攵� 韴瀽毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 韴瀽電� 齑堦赴 230毵� 雼煬搿� 鞁滌瀾頃橂┌, 於旉皜搿� 靹标臣 旮半皹 100毵� 雼煬毳� 韴瀽頃� Axis鞚� 靻岇垬 歆�攵勳潉 頇曤炒頃� 靾� 鞛堧姅 臧�電レ劚鞚� 韽暔霅╇媹雼�.
鞚措矆 韴瀽電� BrainsWay臧� Stella鞐� 韴瀽頃� 瓴冹棎 鞚挫潃 瓴冹溂搿�, Deep TMS Therapy毳� 韽暔頃� 順侅嫚鞝� 鞝曥嫚瓯搓皶 旃橂 鞝戧芳鞚� 臧�靻嶍檾頃橂牑電� 須岇偓 鞝勲灥瓿� 鞚检箻頃╇媹雼�. 韴瀽電� 鞐瓣皠 氤惦Μ搿� 鞚挫瀽臧� 攵欕姅 鞖办劆欤� 順曧儨鞕� 靸來櫂 氅旍护雼堨鞙茧 甑“頇旊悩鞏� Axis臧� 靹滊箘鞀るゼ 頇曥灔頃橁碃 歆�鞐� 頂岆灚韽检棎靹� 雿� 雱撿潃 頇滊彊 氩旍渼搿� 靹膘灔頃� 靾� 鞛堧弰搿� 歆�鞗愴暕雼堧嫟.
BrainsWay (NASDAQ & TASE: BWAY), leader des traitements de neurostimulation non invasive, a annonc茅 un investissement strat茅gique en actions dans Axis Integrated Mental Health, une organisation de gestion de cliniques de sant茅 mentale bas茅e au Colorado. L鈥檌nvestissement comprend un apport initial de 2,3 millions de dollars avec la possibilit茅 d鈥檜n investissement suppl茅mentaire conditionn茅 par des jalons de 1 million de dollars pour une participation minoritaire dans Axis.
Cet investissement fait suite 脿 la prise de participation pr茅c茅dente de BrainsWay dans Stella et s鈥檌nscrit dans la strat茅gie de l鈥檈ntreprise visant 脿 acc茅l茅rer l鈥檃cc猫s 脿 des traitements innovants en sant茅 mentale, notamment leur Deep TMS Therapy. L鈥檕p茅ration sera structur茅e sous forme d鈥檜n titre privil茅gi茅 脿 capitalisation annuelle avec un m茅canisme de rachat, permettant 脿 Axis d鈥櫭﹖endre ses services et de passer d鈥檜ne plateforme r茅gionale 脿 une envergure plus importante.
BrainsWay (NASDAQ & TASE: BWAY), ein f眉hrendes Unternehmen f眉r nichtinvasive Neurostimulationstherapien, hat eine strategische Kapitalbeteiligung an Axis Integrated Mental Health bekanntgegeben, einer in Colorado ans盲ssigen Management-Service-Organisation f眉r psychiatrische Kliniken. Die Beteiligung umfasst eine anf盲ngliche Investition von 2,3 Mio. USD sowie die M枚glichkeit einer zus盲tzlichen meilensteinabh盲ngigen Investition von 1 Mio. USD f眉r eine Minderheitsbeteiligung an Axis.
Die Investition folgt BrainsWays vorheriger Beteiligung an Stella und entspricht der Strategie des Unternehmens, den Zugang zu innovativen Behandlungen im Bereich psychischer Gesundheit, einschlie脽lich der Deep TMS Therapy, zu beschleunigen. Die Finanzierung wird als vorrangiges, j盲hrlich kapitalisiertes Wertpapier mit R眉ckzahlungsmechanismus strukturiert, wodurch Axis seine Dienstleistungen ausbauen und von einer regionalen Plattform zu einer gr枚脽eren Pr盲senz wachsen kann.
- Strategic expansion into mental health service providers through minority stake investments
- Partnership enables broader access to BrainsWay's Deep TMS technology
- Investment structured as preferred security with annual compounding
- Potential for additional $1M milestone-based investment opportunity
- Significant capital outlay of $2.3M with uncertain return timeline
- Limited control due to minority stake position
- Geographic concentration risk with focus on Colorado market
The Investment is part of BrainsWay鈥檚 ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care
BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (鈥淏rainsWay鈥� or the 鈥淐ompany鈥�), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. (鈥淎xis Integrated Mental Health鈥� or 鈥淎xis鈥�), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest
鈥淥ur minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay鈥檚 broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,鈥� said Hadar Levy, Chief Executive Officer of BrainsWay. 鈥淲e see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.鈥�
鈥淎xis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,鈥� concluded Mr. Levy.
鈥淥ur partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,鈥� stated Chris Perez, Chief Executive Officer of Axis. 鈥淕iven the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.鈥�
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS鈩�) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .
About Axis
Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS鈩� and Spravato庐, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof.
For more information, please visit .
Forward-Looking Statement
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥減rojects,鈥� 鈥減redicts,鈥� 鈥渆stimates,鈥� 鈥渁ims,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥減otential鈥� or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company鈥檚 anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company鈥檚 intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 鈥淩isk Factors鈥� in the Company鈥檚 filings with the U.S. Securities and Exchange Commission.
颁辞苍迟补肠迟蝉:听
BrainsWay:
Ido Marom
Chief Financial Officer
Investors:
Brian Ritchie
LifeSci Advisors LLC
FAQ
How much is BrainsWay (BWAY) investing in Axis Integrated Mental Health?
What is the strategic purpose of BWAY's investment in Axis Integrated Mental Health?
How is BrainsWay's investment in Axis structured?
Where does Axis Integrated Mental Health currently operate?
What previous similar investments has BrainsWay made?
